This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, V. A. Articles by Johnson, D. H. Search for Related Content PubMed PubMed Citation Articles by Miller, V. A. Articles by Johnson, D. H.

Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and Opportunities

Vincent A. Miller, Fred R. Hirsch, David H. Johnson

From the Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY; University of Colorado Health Science Center, Aurora, CO; and Vanderbilt Ingram Cancer Center, Nashville, TN

Address reprint requests to Vincent A. Miller, MD, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Room 1012-H Building, 1275 York Avenue, New York, NY 10021; e-mail: millerv{at}mskcc.org.

Bronchioloalveolar cell carcinoma (BAC) has fascinated physicians with its unique epidemiology, pathology, clinical manifestations, and natural history when compared with other non–small-cell lung cancer (NSCLC) subtypes. However, the relative rarity of pure BAC as defined by the WHO, and the inconsistent definitions used in various series, has limited systematic study of this entity. Retrospective and prospective studies suggest that patients with BAC treated with cytotoxic chemotherapy have a longer median survival than those with other subtypes of NSCLC. However, the widely accepted view that BAC is less chemosensitive than other NSCLCs is not clearly supported by the small body of available literature. Antitumor activity of cytotoxic agents and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors has been documented in phase II trials but no phase III trials have been conducted in this disease. The observation that profound responses to gefitinib and erlotinib often occurred in NSCLC patients with BAC, and that EGFR tyrosine kinase domain mutations were identified in large part by careful study of such patients, serves as a paradigm for translational research in this disease. The recognition that pure BAC and adenocarcinoma with BAC features behave similarly and as such represent a relatively common entity will facilitate accrual to BAC specific studies. Alternatively, stratification of these histologic subtypes in broader clinical trials in NSCLC is warranted. However, for either strategy to succeed in advancing our understanding of the molecular biology of BAC, it must be accompanied by central pathologic review with detailed classification of such, and of adequate tissue for measurement of known or putative targets of action of the agent under study.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				R. van Puijenbroek, L. Bosquee, A-P. Meert, D. Schallier, J-C. Goeminne, G. Tits, P. Collard, K. Nackaerts, J-L. Canon, F. Duplaquet, et al. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study Eur. Respir. J., January 1, 2007; 29(1): 128 - 133. [Abstract] [Full Text] [PDF]

				D. J. Raz, B. He, R. Rosell, and D. M. Jablons Current concepts in bronchioloalveolar carcinoma biology. Clin. Cancer Res., June 15, 2006; 12(12): 3698 - 3704. [Full Text] [PDF]

				H. Haneda, H. Sasaki, N. Lindeman, O. Kawano, K. Endo, E. Suzuki, S. Shimizu, H. Yukiue, Y. Kobayashi, M. Yano, et al. A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma Jpn. J. Clin. Oncol., February 1, 2006; 36(2): 69 - 75. [Abstract] [Full Text] [PDF]

				E. Conde, B. Angulo, M. Tang, M. Morente, J. Torres-Lanzas, A. Lopez-Encuentra, F. Lopez-Rios, and M. Sanchez-Cespedes Molecular Context of the EGFR Mutations: Evidence for the Activation of mTOR/S6K Signaling Clin. Cancer Res., February 1, 2006; 12(3): 710 - 717. [Abstract] [Full Text] [PDF]

				K. H. Dragnev, W. J. Petty, S. Shah, A. Biddle, N. B. Desai, V. Memoli, J. R. Rigas, and E. Dmitrovsky Bexarotene and Erlotinib for Aerodigestive Tract Cancer J. Clin. Oncol., December 1, 2005; 23(34): 8757 - 8764. [Abstract] [Full Text] [PDF]